Drug Profile
Caffeine citrate - Nippon Boehringer/Nobelpharma
Alternative Names: Anhydrous caffeine - Nobelpharma/Nippon Boehringer; NPC-11; RespiaLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Nippon Boehringer Ingelheim
- Developer Nippon Boehringer Ingelheim; Nobelpharma
- Class Respiratory stimulants; Small molecules; Xanthines
- Mechanism of Action Purinergic P1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Apnoea
Most Recent Events
- 24 Mar 2014 Registered for Apnoea (In neonates) in Japan (PO)
- 24 Mar 2014 Registered for Apnoea (In neonates) in Japan (IV)
- 31 Oct 2012 Nobelpharma completes a phase III trial in Apnoea (In neonates) in Japan (NCT01408173)